1
|
Devic P, Petiot P. [Distal hereditary motor neuropathy]. Rev Neurol (Paris) 2011; 167:781-90. [PMID: 21529868 DOI: 10.1016/j.neurol.2011.03.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2010] [Revised: 02/15/2011] [Accepted: 03/08/2011] [Indexed: 10/18/2022]
Abstract
INTRODUCTION Distal hereditary motor neuropathy (dHMN), also known as spinal muscular atrophy, represents a group of clinically and genetically heterogeneous diseases caused by degenerations of spinal motor neurons and leading to distal muscle weakness and wasting. Nerve conduction studies reveal a pure motor axonopathy and needle examination shows chronic denervation. STATE OF ART dHMN were initially subdivided into seven subtypes according to mode of inheritance, age at onset, and clinical evolution. Recent studies have shown that these subtypes are still heterogeneous at the molecular genetic level and novel clinical and genetic entities have been characterized. To date, mutations in 11 different genes have been identified for autosomal-dominant, autosomal-recessive, and X-linked recessive dHMN. Most of the genes encode protein involved in housekeeping functions, endosomal trafficking, axonal transport, translation synthesis, RNA processing, oxidative stress response and apoptosis. PERSPECTIVES The pathophysiological mechanisms underlying dHMN seem to be related to the "length-dependent" death of motor neurons of the anterior horn of the spinal cord, likely because their large axons have higher metabolic requirements for maintenance. CONCLUSION dHMN remain heterogeneous at the clinical and molecular genetic level. The molecular pathomechanisms explaining why mutations in these ubiquitously expressed housekeeping genes result in the selective involvement of spinal motor neurons remain to be unravelled.
Collapse
Affiliation(s)
- P Devic
- Service de Neurologie Fonctionnelle et d'Épileptologie, Hôpital Neurologique Pierre-Wertheimer, 59, Boulevard Pinel, 69003 Lyon, France.
| | | |
Collapse
|
2
|
Irobi J, Dierick I, Jordanova A, Claeys KG, De Jonghe P, Timmerman V. Unraveling the genetics of distal hereditary motor neuronopathies. Neuromolecular Med 2006; 8:131-46. [PMID: 16775372 DOI: 10.1385/nmm:8:1-2:131] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/1999] [Revised: 11/30/1999] [Accepted: 11/30/1999] [Indexed: 02/02/2023]
Abstract
The hereditary motor neuronopathies (HMN [MIM 158590]) are a heterogeneous group of disorders characterized by an exclusive involvement of the motor part of the peripheral nervous system. They are usually subdivided in proximal HMN, i.e., the classical spinal muscular atrophy syndromes and distal hereditary motor neuronopathies (distal HMN) that clinically resemble Charcot-Marie-Tooth syndromes. In this review, we concentrate on distal HMN. The distal HMN are clinically and genetically heterogeneous and were initially subdivided in seven subtypes according to mode of inheritance, age at onset, and clinical evolution. Recent studies have shown that these subtypes are still heterogeneous at the molecular genetic level and novel clinical and genetic entities have been delineated. Since the introduction of positional cloning, 13 chromosomal loci and seven disease-associated genes have been identified for autosomal-dominant, autosomal-recessive, and X-linked recessive distal HMN. Most of the genes involved encode protein with housekeeping functions, such as RNA processing, translation synthesis, stress response, apoptosis, and others code for proteins involved in retrograde survival. Motor neurons of the anterior horn of the spinal cord seems to be vulnerable to defects in these housekeeping proteins, likely because their large axons have higher metabolic requirements for maintenance, transport over long distances and precise connectivity. Understanding the molecular pathomechanisms for mutations in these genes that are ubiquitous expressed will help unravel the neuronal mechanisms that underlie motor neuropathies leading to denervation of distal limb muscles, and might generate new insights for future therapeutic strategies.
Collapse
Affiliation(s)
- Joy Irobi
- Peripheral Neuropathy Group, Department of Molecular Genetics, Flanders Interuniversity Institute for Biotechnology, University of Antwerp, Antwerpen, Belgium
| | | | | | | | | | | |
Collapse
|
4
|
McEntagart M, Norton N, Williams H, Teare MD, Dunstan M, Baker P, Houlden H, Reilly M, Wood N, Harper PS, Futreal PA, Williams N, Rahman N. Localization of the gene for distal hereditary motor neuronopathy VII (dHMN-VII) to chromosome 2q14. Am J Hum Genet 2001; 68:1270-6. [PMID: 11294660 PMCID: PMC1226107 DOI: 10.1086/320122] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2001] [Accepted: 03/08/2001] [Indexed: 11/04/2022] Open
Abstract
Distal hereditary motor neuronopathy type VII (dHMN-VII) is an autosomal dominant disorder characterized by distal muscular atrophy and vocal cord paralysis. We performed a genomewide linkage search in a large Welsh pedigree with dHMN-VII and established linkage to chromosome 2q14. Analyses of a second family with dHMN-VII confirmed the location of the gene and provided evidence for a founder mutation segregating in both pedigrees. The maximum three-point LOD score in the combined pedigree was 7.49 at D2S274. Expansion of a polyalanine tract in Engrailed-1, a transcription factor strongly expressed in the spinal cord, was excluded as the cause of dHMN-VII.
Collapse
Affiliation(s)
- Meriel McEntagart
- Institute of Medical Genetics and Department of Psychological Medicine, University Hospital of Wales, Cardiff; Cancer Research Campaign Genetic Epidemiology Group, Strangeways Laboratories, and Cancer Genome Project, Sanger Centre, Wellcome Trust Genome Campus, Cambridge, United Kingdom; Department of Neurology, Hawkes Bay Hospital, Hastings, New Zealand; and Institute of Neurology, Queen Square, London
| | - Nadine Norton
- Institute of Medical Genetics and Department of Psychological Medicine, University Hospital of Wales, Cardiff; Cancer Research Campaign Genetic Epidemiology Group, Strangeways Laboratories, and Cancer Genome Project, Sanger Centre, Wellcome Trust Genome Campus, Cambridge, United Kingdom; Department of Neurology, Hawkes Bay Hospital, Hastings, New Zealand; and Institute of Neurology, Queen Square, London
| | - Hywel Williams
- Institute of Medical Genetics and Department of Psychological Medicine, University Hospital of Wales, Cardiff; Cancer Research Campaign Genetic Epidemiology Group, Strangeways Laboratories, and Cancer Genome Project, Sanger Centre, Wellcome Trust Genome Campus, Cambridge, United Kingdom; Department of Neurology, Hawkes Bay Hospital, Hastings, New Zealand; and Institute of Neurology, Queen Square, London
| | - M. Dawn Teare
- Institute of Medical Genetics and Department of Psychological Medicine, University Hospital of Wales, Cardiff; Cancer Research Campaign Genetic Epidemiology Group, Strangeways Laboratories, and Cancer Genome Project, Sanger Centre, Wellcome Trust Genome Campus, Cambridge, United Kingdom; Department of Neurology, Hawkes Bay Hospital, Hastings, New Zealand; and Institute of Neurology, Queen Square, London
| | - Melanie Dunstan
- Institute of Medical Genetics and Department of Psychological Medicine, University Hospital of Wales, Cardiff; Cancer Research Campaign Genetic Epidemiology Group, Strangeways Laboratories, and Cancer Genome Project, Sanger Centre, Wellcome Trust Genome Campus, Cambridge, United Kingdom; Department of Neurology, Hawkes Bay Hospital, Hastings, New Zealand; and Institute of Neurology, Queen Square, London
| | - Philip Baker
- Institute of Medical Genetics and Department of Psychological Medicine, University Hospital of Wales, Cardiff; Cancer Research Campaign Genetic Epidemiology Group, Strangeways Laboratories, and Cancer Genome Project, Sanger Centre, Wellcome Trust Genome Campus, Cambridge, United Kingdom; Department of Neurology, Hawkes Bay Hospital, Hastings, New Zealand; and Institute of Neurology, Queen Square, London
| | - Henry Houlden
- Institute of Medical Genetics and Department of Psychological Medicine, University Hospital of Wales, Cardiff; Cancer Research Campaign Genetic Epidemiology Group, Strangeways Laboratories, and Cancer Genome Project, Sanger Centre, Wellcome Trust Genome Campus, Cambridge, United Kingdom; Department of Neurology, Hawkes Bay Hospital, Hastings, New Zealand; and Institute of Neurology, Queen Square, London
| | - Mary Reilly
- Institute of Medical Genetics and Department of Psychological Medicine, University Hospital of Wales, Cardiff; Cancer Research Campaign Genetic Epidemiology Group, Strangeways Laboratories, and Cancer Genome Project, Sanger Centre, Wellcome Trust Genome Campus, Cambridge, United Kingdom; Department of Neurology, Hawkes Bay Hospital, Hastings, New Zealand; and Institute of Neurology, Queen Square, London
| | - Nick Wood
- Institute of Medical Genetics and Department of Psychological Medicine, University Hospital of Wales, Cardiff; Cancer Research Campaign Genetic Epidemiology Group, Strangeways Laboratories, and Cancer Genome Project, Sanger Centre, Wellcome Trust Genome Campus, Cambridge, United Kingdom; Department of Neurology, Hawkes Bay Hospital, Hastings, New Zealand; and Institute of Neurology, Queen Square, London
| | - Peter S. Harper
- Institute of Medical Genetics and Department of Psychological Medicine, University Hospital of Wales, Cardiff; Cancer Research Campaign Genetic Epidemiology Group, Strangeways Laboratories, and Cancer Genome Project, Sanger Centre, Wellcome Trust Genome Campus, Cambridge, United Kingdom; Department of Neurology, Hawkes Bay Hospital, Hastings, New Zealand; and Institute of Neurology, Queen Square, London
| | - P. Andrew Futreal
- Institute of Medical Genetics and Department of Psychological Medicine, University Hospital of Wales, Cardiff; Cancer Research Campaign Genetic Epidemiology Group, Strangeways Laboratories, and Cancer Genome Project, Sanger Centre, Wellcome Trust Genome Campus, Cambridge, United Kingdom; Department of Neurology, Hawkes Bay Hospital, Hastings, New Zealand; and Institute of Neurology, Queen Square, London
| | - Nigel Williams
- Institute of Medical Genetics and Department of Psychological Medicine, University Hospital of Wales, Cardiff; Cancer Research Campaign Genetic Epidemiology Group, Strangeways Laboratories, and Cancer Genome Project, Sanger Centre, Wellcome Trust Genome Campus, Cambridge, United Kingdom; Department of Neurology, Hawkes Bay Hospital, Hastings, New Zealand; and Institute of Neurology, Queen Square, London
| | - Nazneen Rahman
- Institute of Medical Genetics and Department of Psychological Medicine, University Hospital of Wales, Cardiff; Cancer Research Campaign Genetic Epidemiology Group, Strangeways Laboratories, and Cancer Genome Project, Sanger Centre, Wellcome Trust Genome Campus, Cambridge, United Kingdom; Department of Neurology, Hawkes Bay Hospital, Hastings, New Zealand; and Institute of Neurology, Queen Square, London
| |
Collapse
|